Neurocrine Biosciences, Inc. Q2 2026 Earnings Recap

Neurocrine Biosciences shares declined 7.7% after the quarter as investors reacted negatively to margin compression and elevated acquisition-related expenses overshadowing strong top-line growth.

Key Takeaways

• Total revenue exceeded $950 million, reflecting nearly 40% year-over-year growth, driven by INGREZZA, CRENESSITY, and first contributions from VYKAT XR.
• INGREZZA sales rose 15% year-over-year to $716 million, prompting raised full-year revenue guidance to approximately $2.85 billion.
• CRENESSITY continued solid launch execution with $184 million in sales and prescriber adoption at roughly 15% of the estimated diagnosed population.
• VYKAT XR contributed $54 million in Neurocrine-recognized sales for the quarter post-acquisition, with integration progressing but market development still ongoing.
• The $2.9 billion acquisition of Soleno generated $130 million in acquisition-related costs this quarter and non-cash amortization expense of $20 million, pressuring operating margins and financial results.